Medical News

RSS

Androgen receptor an additional hormonal target in many breast cancers

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.

5 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation System.

5 Jun 2012

New evidence to support a range of healthy behaviors

Five new studies provide evidence to support simple steps we can take to prevent illness and improve our overall health. In the June issue of The American Journal of Medicine, researchers report on fish consumption to reduce the risk of colon cancer; the effectiveness ofhypnotherapy and acupuncture for smoking cessation; regular teeth cleaning to improve cardiovascular health; the effectiveness of primary care physicians in weight loss programs; and the use of low-dose aspirin to reduce cancer risk.

5 Jun 2012

Nouveau Life launches new weight loss supplement

Nouveau Life Pharmaceuticals Inc., a leading provider of quality all-natural dietary supplements, announced today the release of its newest supplement product: New Life Naturals: For Your Weight Loss.

5 Jun 2012

$25 million grant announced to improve states' care for frail elderly; Calif. seeks changes for those eligible for Medicare and Medicaid

Stateline reports on a new HHS grant to help low-income adults with mental and physical disabilities remain in their communities. Meanwhile, California submits a plan to federal officials for the transition of dual eligibles to managed care.

5 Jun 2012

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia.

4 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris Inc. today announced that Johanna Bendell, MD, Director of Gastrointestinal Cancer Research and Associate Director of Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, presented Phase 3 results for perifosine in refractory colorectal cancer yesterday, at the American Society of Clinical Oncology (ASCO) Annual Meeting which is being held in Chicago.

4 Jun 2012

ProStrakan, Orexo reconfigure commercial rights to Abstral

Orexo AB and ProStrakan Group plc jointly announce today that the companies have reconfigured the commercial rights to the product, Abstral, in various territories worldwide.

4 Jun 2012

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.

4 Jun 2012

AcelRx completes private placement of common stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012.

4 Jun 2012

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.

4 Jun 2012

First Edition: June 4, 2012

Today's headlines include the latest news on implementation of the health law, on the pending Capitol Hill effort to repeal the medical device tax and reports from the states.

4 Jun 2012

ShangPharma celebrates 10th anniversary of partnership with Lilly

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today celebrated the 10th anniversary of its partnership with Eli Lilly and Company.

4 Jun 2012

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.

4 Jun 2012

Prisoners need education on the appropriate use of topical antibiotic products

Prisoners need education on the appropriate use of topical antibiotic products, according to a study released today at the 39th Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

4 Jun 2012

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

4 Jun 2012

New group-based learning approach for children with asthma

Many children suffers from asthma and to deal with everyday life can be hard for children and parents. They need knowledge. "To understand the children's challenges in everyday life health professionals should ask the child and also listen to them", says Anne Trollvik that is a nurse and an university lecturer.

4 Jun 2012

Regular and moderate exercise most beneficial for cardiovascular health

Micah True, legendary ultra-marathoner, died suddenly while on a routine 12-mile training run March 27, 2012. The mythic Caballo Blanco in the best-selling book, Born to Run, True would run as far as 100 miles in a day. On autopsy his heart was enlarged and scarred; he died of a lethal arrhythmia (irregularity of the heart rhythm). Although speculative, the pathologic changes in the heart of this 58 year-old veteran extreme endurance athlete may have been manifestations of "Phidippides cardiomyopathy," a condition caused by chronic excessive endurance exercise.

4 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012